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Summary. There is evidence to suggest that glutamate and other excitatory 
amino acids play an important role in the regulation of neuronal excitation. 
Glutamate receptor stimulation leads to a non-physiological increase of intra-
cellular free C a 2 + . Disturbed C a 2 + homeostasis and subsequent radical 
formation may be decisive factors in the pathogenesis of neurodegenerative 
diseases. 
Decreased glutamatergic activity appears to contribute to paranoid 
hallucinatory psychosis in schizophrenia and pharmacotoxic psychosis in 
Parkinson's disease. It has been suggested that a loss of glutamatergic function 
causes dopaminergic over-activity. Imbalances of glutamatergic and dopaminer-
gic systems in different brain regions may result in anti-akinetic effects or 
the occurrence of psychosis. The simplified hypothesis of a glutamatergic-
dopaminergic (im)-balancc may lead to a better understanding of motor 
behaviour and psychosis. 
Introduction 
It is only recently that excitatory amino acid receptors have been dis-
covered. Through the use of selective agonists and antagonists it has 
become evident that these receptors consist of different subtypes (for review 
see Watkins et a l . , 1990). A t present the most useful classification provides 
the following excitatory amino acid receptor subtypes: N-methyl-D-aspartate 
( N M D A ) receptors, kainate receptors, quisqualate receptors or a-amino-3-
hydroxy-5-methyl-4-isoxazolepropionate ( A M P A ) receptors, metabotropic 
receptors and L-aminophosphonobutyrate (L -AP4) receptors. Some im-
portant features of these excitatory amino acid receptor subtypes are given 
in Table 1. It is evident that these receptors fulfill a variety of different 
physiological functions depending on their regional and subregional 
location, their pre- or postsynaptic localization, the neurotransmitter system 
at which they are located and their quantitative distribution. 
Table 1. Glutamate receptor subtypes: major pharmacological profile and localization 
Glutamate receptor subtype Agonist Antagonist Modulating system Ionic channel Localization 
N M D A 
A M P A 
Kainate 
L - A P 4 
Metabotropic 
N M D A 
L-aspartate 
L-glutamate 
quisqualate 
A M P A 
glutamate 
kainate, domoate 
L - A P 4 
L-serine-O-phosphate 
quisqualate, ibotenate 
A C P D 
P C P 
Ketamine 
MK-801 
SKF-10047 
M g + + 
" " N T C - ' 
C P P 
D - A P 5 
C G S 19755 
D A A 
C . 
C N Q X 
N B Q X 
D G G 
G D E E 
babiturates 
philanthotoxin 
polyamines 
glycine + 
D-serine + 
M N Q X -
7-chlorokynurenate 
H A 966 
L - A P 3 
L - A P 4 
N a + 
K + 
C a 2 + 
postsynaptic 
N a + 
K a + 
postsynaptic, glial 
N O 
coupling to 
PLC-system 
and via IP 3 
influences 
intracellular 
C a 2 + stores 
presynaptic 
presynaptic 
postsynaptic, glial 
Abbreviations: C. competitive; N.C. non-competitive; ACPD 1-amino-cyclopentane-l, 3-dicarboxylic acid; AMPA a-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid; D-AP5 D-2-amino-5-phosphonopentanoic acid; L-AP3 L-amino-3-phosphonopropionic acid; L-AP4 
L-2-amino-4-phosphonobutanoic acid; CGS 19755 4-phosphonomethyl-2-piperidinecarboxylic acid; CNQX 6-cyano-7-nitroquinoxaline-2, 
3-dione; CPP (±)-2-carboxypiperazine-4-yl-propyl-l-phosphonic acid; DAA D-aminoadipate; DGG D-glutamylglycine; GDEE glutamic 
acid diethyl ester; HA 966 l-hydroxy-3-amino-pyrrolidin-2-one; MK80I ( + )-5~methyl-10, 1 l-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-
imine maleate; MNQX 6,8-dinitroquinoxalinedione; NBQX 6-nitro-7-sulphamobenzoff]quinoxalinc-2,3-dione; NMD A N-methyl-D-
aspartate; NO nitric oxide; PCP phencyclidine; SKF-10047 N-allyl-normetazocine; 4- activating; - inhibiting 
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N M D A receptors are involved in the regulation of intracellular free 
Ca 2 + -concentrations. It has therefore been suggested that glutamate and 
other excitatory amino acids play an important role in the regulation of 
neuronal excitation and may bring about neuronal destruction if admin-
istered in sufficient excess. 
Glutamate toxicity and neurodegeneration 
The regulation of C a 2 + and its compartmentalization is important for 
both presynaptic and postsynaptic events. Alterations in the extracellular/ 
intracellular C a 2 + ratio can produce deleterious changes in cell function. 
Al tered C a 2 + homeostasis may influence a variety of physiological cell 
functions including C a 2 + transport systems, C a 2 + binding proteins and 
Ca 2 + -act ivated proteases (Gibson and Peterson, 1987). A non-physiological 
increase of intracellular free C a 2 + leads therefore to a dysregulation of 
membrane-dependent processes. This is generally accompanied by a loss of 
energy supply to the cell, and the loss of A T P in particular alters the 
biochemical homeostasis of the cell. 
Neurodegeneration is caused or accompanied by C a 2 + influx and intra-
cellular C a 2 + mobilization. It has been suggested that excitatory amino 
acids play an important role in excitatory neurotoxicity and neurodegenera-
tion (for review see Meldrum and Garthwaite, 1990). Glutamate with its 
high concentration in the mammalian brain is the probable neurotransmitter 
at most excitatory synapses and the most likely excitatory amino acid toxin. 
N M D A receptor channels permit a large C a 2 + influx and there is evidence 
to suggest that toxic C a 2 + entry occurs mainly through these channels 
(Garthwaite and Garthwaite, 1987). The activation of proteases and other 
C a 2 f-dependent enzymes such as protein kinase C , phospholipases and 
Ca 2 + -calmodulin-dependent protein kinase II may contribute to glutamate 
toxicity (Meldrum and Garthwaite, 1990). The substantial increase of C a 2 + -
activated proteases such as calpains causes destruction of microtubules, 
neurofilaments, etc. and may induce derangement of structural membrane 
integrity. Calpains also convert xanthine dehydrogenase to xanthine oxidase 
and free radicals are subsequently generated during purine metabolism. 
Increased phospholipase activity results in the release of lipids and leads to 
production of arachidonic acid, which can be metabolized to produce free 
radicals. Radicals increase lipid peroxidation of membrane constituents and 
enhance the release of excitatory amino acids. In addition, arachidonic acid 
blocks the uptake of glutamate into glial and neuronal cells. 
A l l of these pathological events cause a catabolic state in which nu-
tritional supply decreases. Neuronal processes are eventually destroyed and 
neurodegeneration becomes uncontrolled and progressive. In Parkinson's 
disease and in Alzheimer 's dementia a loss of about 70% of cell bodies 
in the substantia nigra pars compacta and the nucleus basalis Meynert, 
respectively, is necessary before the major clinical symptoms are observed. 
Whether or not disturbed C a 2 + homeostasis and radical formation are 
decisive pathobiochemical factors in these disorders is the subject of 
intensive research. 
There is experimental evidence to suggest that excitotoxic mechanisms 
contribute to neuronal loss occurring as the result of cerebral ischaemia (for 
review see Meldrum and Garthwaite, 1990). Current knowledge suggests 
that a loss of glutamatergic function is a plausible hypothesis for the occur-
rence of productive symptoms in schizophrenia (see below). Decreased 
glutamatergic function may in theory be accompanied by a reduced rate of 
cerebral infarction in patients with schizophrenia. In order to examine this 
proposition we took an unselected series of 880 patients with neurological 
or psychiatric diseases who died at Lainz Geriatric Hospital , Vienna, be-
tween 1981 and 1988. In addition to routine autopsy, examinations were 
performed by a neuropathologist (K . J.). The number and percentage 
of patients dying of cerebral infarction was determined for the various 
diagnoses (Table 2). The number of such deaths was highest in the group of 
patients with a history of cerebral infarction. In contrast to neurological 
diseases, psychiatric disorders showed the lowest death rate caused by 
cerebral infarction. This preliminary evaluation is in line with the theories 
of decreased glutamatergic activity in schizophrenia and enhanced excitatory 
amino acid release in patients with cerebral infarction. It is interesting to 
note that cerebral infarction was not found in a group of 40 depressed 
patients. It is not known whether this can be directly related to decreased 
glutamatergic activity or to antidepressant therapy which may antagonize 
N M D A receptor function (Reynolds and Mi l l e r , 1988). 
Table 2. Neurological and psychiatric patients dying of neuropathologically confirmed 
cerebral infarction (1981-1988) 
Disease Patients Sex Age (n) Presumed Cerebral 
(n) F / M <65 >65 N M D A infarction 
years receptor as cause 
density of death 
N % 
Cerebral infarction 77 48/29 13 64 T 1 21 27 
Dementia + cerebro- 522 313/209 58 464 t = 1 52 10 
vascular insufficiency 
Parkinson's disease 34 21/13 4 30 T i 3 11 
Other neurol. disorders 45 18/27 25 20 T 9 20 
(Huntington's disease, 
multiple sclerosis) 
Dementia of Alzheimer type 64 6/58 45 19 T 1 3 5 
Schizophrenia 105 66/39 45 60 1 1 1 
Depression 40 29/11 7 33 9 0 0 
N M D A receptor densities are presumed to be increased ( f ), decreased ( | ) or 
unaltered (=) in comparison with control subjects. Increased, decreased or unaltered 
pathway activity may occur in the same disease depending on the loop systems in-
volved. The quantity of change, however, is dependent on the progress and duration of 
the disease. This information is not given here 
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The role of glutamate in schizophrenia 
It has recently been postulated that decreased glutamatergic function is a 
pathobiochemical marker of schizophrenia (K im et a l . , 1980). A decreased 
release of glutamate has been found in the frontal and temporal cortex 
of schizophrenic patients (Sherman et a l . , 1991) while increased N M D A 
receptor density has been measured in the temporal and parietal cortex 
(Suga et a l . , 1990). In the putamen, increased (Kornhuber et a l . , 1989) and 
unaltered (Suga et a l . , 1990; Weissman et a l . , 1991) N M D A receptor 
densities have been reported. Quisqualate receptors are not changed in the 
frontal, temporal and parietal cortex (Kurumaji et al . , 1990) while kainate 
receptor binding is increased in the frontal cortex (Deakin et a l . , 1989; 
Nishikawa et a l . , 1983) and not changed (Deakin et a l . , 1989) or decreased 
(Kerwin et a l . , 1988; Harrison et a l . , 1991) in the hippocampus. Taken 
together, the data available is of value only as a starting point for further 
research since both the number of studies and the number of brain regions 
examined are limited. For example, the most vulnerable brain regions in 
schizophrenia, the entorhinal cortex (Jakob and Beckmann, 1986) and the 
prefrontal cortex (Benes et a l . , 1986), have not been studied in detail 
and only preliminary biochemical evidence exists to suggest that N M D A 
receptor density is marginally increased in the entorhinal cortex (Kornhuber 
et a l . , 1989). 
We assume that it is the loss of glutamatergic activity that induces an 
enhanced dopaminergic tone. The ^'dopamine hypothesis 1 ' of schizophrenia 
suggesting dopaminergic overactivity in the pathobiochemistry of some 
productive symptoms (paranoid hallucinatory psychosis) seems to be valid 
according to this assumption (Kornhuber et a l . , 1990). 
Anti-akinetic effects of glutamate antagonists and pharmacotoxic psychosis 
In Parkinson's disease enhanced glutamatergic activity is assumed to occur 
in the nucleus subthalamicus due to a decreased G A B A e r g i c input from the 
lateral globus pallidus. The cortico-striatal fibres also appear to be function-
ally over-active as the result of decreased dopaminergic nigrostriatal activity. 
B y contrast, the glutamatergic thalamocortical pathway shows reduced 
activity due to G A B A e r g i c influence on the ventrolateral thalamus (Riederer 
and Berger, 1991). 
The only anti-glutamatergic drugs available for the treatment of 
Parkinson's disease are the non-competitive N M D A receptor antagonists 
amantadine and memantine, which have only moderate anti-akinetic 
efficacy compared to dopamimetic substances (Schwab et a l . , 1969). How-
ever, threshold doses of memantine producing mild anti-akinetic effects 
result in pharmacotoxic psychosis in an unexpectedly high proportion 
of patients (Riederer et a l . , 1991). Amantadine is known to have anti-
parkinsonian effects and pharmacotoxic psychoses are frequent adverse 
reactions (Danielczyk, 1973). In Parkinson's disease there is a lack of data 
Response Response 
ANTI-AKINETIC ANTI-KINETIC 
INDUCTION of PSYCHOSIS IMPROVEMENT of PSYCHOSIS ? 
Dopamimetics 
L-Dopa 
Bromocriptine 
Lisuride 
L-Deprenyl 
Anticholinergics 
Dopamine 
antagonists 
Neuroleptics 
ANTI-KINETIC ANTI-AKINETIC 
IMPROVEMENT of PSYCHOSIS INDUCTION of PSYCHOSIS 
Fig. 1. Simplified illustration of glutamatergic-dopaminergic imbalances: anti-akinetic 
effects and psychosis 
confirming a disturbance of glutamatergic function in limbic and cortical 
areas and supporting a glutamatergic hypothesis of pharmacotoxic psychosis. 
However, the fact that memantine has a considerable potential to induce 
pharmacotoxic psychosis at threshold doses which produce minor anti-akinetic 
effects, could suggest that glutamatergic activity in areas responsible for 
psychosis is reduced. Since under-active glutamatergic systems are further 
inhibited by N M D A receptor antagonists, adverse reactions such as 
pharmacotoxic psychosis are more likely to occur. 
It is well known that all dopamimetic substances cause pharmacotoxic 
psychosis in Parkinson's disease and are able to aggravate productive 
symptoms in schizophrenia. It is not known, however, whether competitive 
N M D A receptor antagonists, which are known to enhance locomotor activity 
in experimental animals (Svensson et a l . , 1991; Loschmann et a l . , 1991), 
have potent anti-akinetic efficacy in Parkinson's disease or whether these 
substances also create the adverse reactions of dopamimetics and non-
competitive N M D A receptor antagonists. The development of competitive 
glutamatergic antagonists or of partial agonists/antagonists could be another 
strategy capable of producing anti-akinetic effects with only mild side-
effects. A simplified summary of this hypothesis is given in Fig. 1. 
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